logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy PLC making LIGHT work of cancer breakthrough

The company said it is now testing the Proton Source for its LIGHT system in situ in France.

CancerHeadline.jpg
Proton beam therapy is expected to become a go-to cancer treatment.
A company that uses technology developed by scientists working on the large hadron collider at the CERN facility in Switzerland has moved a step closer to creating a low-cost proton beam treatment for cancer.

AIM-listed Advanced Oncotherapy PLC (LON:AVO) said it is now testing the Proton Source for its LIGHT system in situ in France. Once the testing process has been complete it will be shipped to AVO’s facility in Geneva.

LIGHT is an acronym given to the firm’s Linac Image Guided Hadron Technology.

Cheaper and smaller than the current units, which are almost prohibitively expensive, the LIGHT system has the ability to propel protons at the speed of the larger machines.

Proton beam therapy is expected to emerge as the go-to treatment for tumours as the price of the technology comes down. It uses the aforementioned protons to pinpoint tumours more precisely. This limits the damage caused by radiation to surrounding tissue and organs as well as offering patients higher disease-free survival rates. 

The piece of the kit that accelerates the protons was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the "God particle".

Of the latest developments, AVO boss Michael Sinclair said: "The team at Advanced Oncotherapy have been working hard in progressing the construction of our first LIGHT system and I am delighted that we remain on track and delivering to the timeline that we originally presented to shareholders in November 2014.

“Our LIGHT system combines some remarkable technology and it is very pleasing to see it continue to take shape - once completed we will have developed a game-changing type of proton therapy that will allow this specialist treatment to be available for cancer patients in a much more effective and affordable way."

 

Quick facts: Advanced Oncotherapy PLC

Price: 37.5 GBX

LSE:AVO
Market: LSE
Market Cap: £91.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: VR Education's ENGAGE platform to be included in new 5G VR...

Headlines from the Proactive UK newsroom. VR Education’s (LON:VRE) Engage platform has been chosen as an embedded title in a new 5G virtual reality headset being developed by a consortium of Deutsche Telekom, Qualcomm and XRSPACE. The new headset is due to launch in...

1 week, 4 days ago

RNS

Holding(s) in Company

1 week, 5 days ago

Total Voting Rights

2 weeks, 2 days ago

Holding(s) in Company

2 weeks, 3 days ago

Total Voting Rights

on 6/11/19

Change of Broker

on 10/10/19

Total Voting Rights

on 30/9/19

2 min read